News & Insights

Markets
BNTX

BioNTech Up 6% As Pfizer-BioNTech Covid Vaccine Approved For Infants

October 12, 2022 — 10:05 am EDT

Written by RTTNews.com for RTTNews ->

(RTTNews) - Shares of Covid-19 vaccine maker BioNTech SE (BNTX) are rising more than 6% Wednesday morning at $137.95.

Today, FDA stated that it authorized Pfizer-BioNTech bivalent COVID-19 Vaccine to be used as a booster dose in children below five years of age.

BNTX has traded in the range of $117.08-$374.58 in the last 1 year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source ->

Stocks mentioned

BNTX

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.